What 5 Analyst Ratings Have To Say About Ocular Therapeutix
Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst ratings within the last quarter:
How The Future Looks For Last Week’s Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More
Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have in the cards going forward.
10 Biggest Price Target Changes For Monday
Wells Fargo boosted Bank of America Corporation (NYSE: BAC) price target from $55 to $60. Bank of America shares rose 0.4% to $47.76 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Lowers Price Target to $14
HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and lowers the price target from $18 to $14.
Mid-Afternoon Market Update: Nasdaq Down 70 Points; Ocular Therapeutix Shares Drop
Toward the end of trading Friday, the Dow traded up 0.23% to 35,685.44 while the NASDAQ fell 0.46% to 15,145.51. The S&P also fell, dropping 0.01% to 4,549.46.
Mid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump
Midway through trading Friday, the Dow traded up 0.25% to 35,690.68 while the NASDAQ fell 0.46% to 15,145.78. The S&P also rose, gaining 0.02% to 4,550.53.
Ocular Therapeutix Announces Topline Results For Phase 2 Clinical Trial Of OTX-CSI For The Treatment Of Dry Eye Disease Did Not Meet Primary Endpoint
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline